The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR

Abstract

The prognoses of patients with E545K mutation were worse than patients without this mutation. The E545K mutation promoted GBC progression through enhanced binding to EGFR and activating downstream akt activity. The PI3K selective inhibitor, A66, suppressed gallbladder carcinoma proliferation.